Wall Street Zen Downgrades Progyny (NASDAQ:PGNY) to Hold

Progyny (NASDAQ:PGNY) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

Other analysts have also recently issued reports about the stock. BTIG Research cut their price target on shares of Progyny from $35.00 to $30.00 and set a “buy” rating on the stock in a report on Thursday, March 5th. Jefferies Financial Group reissued a “buy” rating and set a $30.00 price objective on shares of Progyny in a report on Friday, March 6th. Barclays cut their target price on shares of Progyny from $29.00 to $23.00 and set an “overweight” rating on the stock in a research note on Friday, March 20th. Canaccord Genuity Group reduced their price target on shares of Progyny from $26.00 to $19.00 and set a “hold” rating on the stock in a research report on Wednesday, March 11th. Finally, Citizens Jmp upgraded Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 price target for the company in a research note on Tuesday, January 20th. Nine equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.91.

Progyny Price Performance

Shares of PGNY stock opened at $16.60 on Friday. Progyny has a fifty-two week low of $16.28 and a fifty-two week high of $28.75. The firm’s 50 day moving average price is $19.77 and its two-hundred day moving average price is $22.16. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of 25.54, a price-to-earnings-growth ratio of 0.96 and a beta of 0.99.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, February 26th. The company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. Progyny had a return on equity of 11.37% and a net margin of 4.54%.The business had revenue of $318.40 million during the quarter, compared to analyst estimates of $314.26 million. During the same quarter last year, the firm earned $0.42 earnings per share. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. On average, equities analysts forecast that Progyny will post 0.6 EPS for the current fiscal year.

Insider Activity

In related news, EVP Allison Swartz sold 4,657 shares of the stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total value of $81,031.80. Following the completion of the transaction, the executive vice president owned 89,879 shares in the company, valued at $1,563,894.60. This represents a 4.93% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders sold a total of 7,455 shares of company stock valued at $129,515 over the last ninety days. Corporate insiders own 9.40% of the company’s stock.

Institutional Investors Weigh In On Progyny

A number of institutional investors and hedge funds have recently bought and sold shares of PGNY. Wellington Management Group LLP boosted its stake in shares of Progyny by 260.9% during the 4th quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock worth $57,607,000 after acquiring an additional 1,621,688 shares in the last quarter. Loomis Sayles & Co. L P acquired a new stake in shares of Progyny during the fourth quarter worth $19,917,000. Barclays PLC lifted its holdings in shares of Progyny by 79.2% during the third quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock valued at $33,904,000 after purchasing an additional 696,447 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of Progyny by 37.6% during the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after purchasing an additional 545,431 shares during the last quarter. Finally, Nomura Holdings Inc. acquired a new position in shares of Progyny in the 2nd quarter valued at $9,368,000. 94.93% of the stock is owned by institutional investors and hedge funds.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.